Newbridge Financial Services Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Newbridge Financial Services Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-81	Closed	-$4.4K	–	1221
2025 Q3	$4.4K	Sell	81 -22	-21%	-$1.26K	﹤0.01%	1039
2025 Q2	$5.66K	Buy	+103	New	+$6.07K	﹤0.01%	1006
2023 Q4	–	Sell	-38	Closed	-$3.36K	–	1180
2023 Q3	$3.36K	Hold	38	–	–	﹤0.01%	1012
2023 Q2	$3.29K	Hold	38	–	–	﹤0.01%	1075
2023 Q1	$3.69K	Hold	38	–	–	﹤0.01%	1117
2022 Q4	$3.93K	Hold	38	–	–	﹤0.01%	1106
2022 Q3	$3K	Hold	38	–	–	﹤0.01%	1113
2022 Q2	$3K	Sell	38 -16	-30%	-$1.27K	﹤0.01%	1090
2022 Q1	$4K	Hold	54	–	–	﹤0.01%	1128
2021 Q4	$5K	Sell	54 -484	-90%	-$39.9K	﹤0.01%	1059
2021 Q3	$42K	Hold	538	–	–	0.03%	461
2021 Q2	$45K	Buy	538 +500	+1,316%	+$39.6K	0.03%	473
2021 Q1	$3K	Buy	+38	New	+$3.1K	﹤0.01%	1106

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Newbridge Financial Services Group's BMRN Position: Q4 2025 in Review

Newbridge Financial Services Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 81 shares — an estimated $4.4K sold.

Newbridge Financial Services Group first reported a position in BMRN in Q1 2021 and held it in 13 quarters. The position peaked at $45K in Q2 2021. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Newbridge Financial Services Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Newbridge Financial Services Group sold 81 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $4.4K.
Newbridge Financial Services Group first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 13 quarters.
Newbridge Financial Services Group's BioMarin Pharmaceuticals position peaked at $45K in Q2 2021.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Newbridge Financial Services Group's 13F filing for Q4 2025, filed 21 Jan 2026.